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REPORTS ON THERAPY 
Emergent Coronary Angioplasty in the Treatment of Acute Ischemic 
Mitral Regurgitation: Long-Term Results in Five Cases 
FAYAZ A. SHAWL, MD, FACC,* MERVYN B. FORMAN, MD, FACC,t 
SUDHAKAR PUNJA, MD, FACC,* THOMAS S. GOLDBAUM, MD, FACC* 
Takoma Park, Maryland and Nashville, Tennessee 
Severe mitral regurgitation in the setting of an evolving 
myocardial infarction is associated with a high operative 
mortality rate. Five patients with acute severe mitral re- 
gurgitation secondary to ischemic posterior papillary mus- 
cle dysfunction underwent emergent percutaneous trans- 
luminal coronary angioplasty. Two patients were in 
cardiogenic shock and required intraaortic balloon coun- 
terpulsation. Angioplasty resulted in rapid improvement in 
hemodynamic variables, and all patients were discharged at 
a mean of 10 days after the procedure. 
Long-term follow-up study (mean 35 + 6 months) 
revealed normal mitral valve function angiographically and 
The occurrence of significant mitral regurgitation in the 
setting of an evolving myocardial infarction usually results 
from severe ischemic dysfunction of the posterior papillary 
muscle (l-3). Restoration of blood flow in this setting is 
mandatory to prevent acute papillary muscle rupture or 
fibrosis with subsequent chronic mitral regurgitation (4S). 
Because most cases of ischemic papillary muscle dysfunc- 
tion are not associated with significant left ventricular dys- 
function, correction of the hemodynamic lesion would be 
associated with a favorable long-term survival (4). 
Surgical treatment of ischemic mitral regurgitation often 
requires both valve replacement and coronary artery bypass 
surgery and is associated with a high mortality rate (6-10). 
Since its introduction in 1977, percutaneous transluminal 
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by Doppler echocardiography in four patients. Repeat 
angioplasty was required in one patient, and another 
underwent coronary artery bypass surgery without valve 
replacement for restenosis. One patient developed progres- 
sive mitral regurgitation and required elective mitral valve 
replacement 12 months after angioplasty. 
These preliminary findings suggest that emergent coro- 
nary angioplasty is a useful therapeutic intervention in the 
treatment of ischemic mitral regurgitation and is associated 
with a favorable long-term outcome. 
(J Am Co11 Cardiol1989;14:986-91) 
coronary angioplasty has been successfully applied to a large 
subset of patients with ischemic heart syndromes including 
unstable angina, multivessel coronary artery disease and 
acute myocardial infarction with and without cardiogenic 
shock (11-15). In this report, we describe five patients with 
acute severe mitral regurgitation secondary to ischemic 
papillary muscle dysfunction who underwent emergent cor- 
onary angioplasty of the culprit lesion. Sustained long-term 
benefit was obtained in four patients; one patient required 
elective mitral valve replacement for progressive mitral 
regurgitation 12 months after angioplasty. 
Methods 
Study patients (Table 1). From June 1982 to January 
1986, 150 patients underwent emergent percutaneous trans- 
luminal coronary angioplasty at Washington Adventist Hos- 
pital for the treatment of evolving myocardial infarction. 
Five patients had evidence of moderate or severe acute 
mitral regurgitation secondary to ischemic papillary muscle 
dysfunction and they form the basis of this report. Their ages 
ranged from 43 to 82 years (mean 59); there were two men 
and three women. All patients manifested radiographic evi- 
dence of pulmonary edema on presentation (Fig. 1). All 
patients were in New York Heart Association functional 
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Table 1. Clinical and Biochemical Features in Patients With Ischemic Mitral Regurgitation 
Interval From 
Patient Age (yr) Infarct Chest Pain to Pulmonaq Peak Cpk 
No. & Gender L.ocation PTCA (h) Edema (IUWer) Comments 
I 53M Inferior 4.0 Yes 1.226 
2 43f- Inferior x.0 Yes 5,286 Intubated. IABP, heart block. streptokinase 
3 H?F Posterior I.5 Ye5 2.344 Intubated. IABP. heart block. streptokinase 
4 5%~ Inferior 3.0 Ye\ 3.426 Streptokinase 
s 65t Inferior 2.5 Yes I .2x Chronic renal failure 
Cpk = creatine kinase; F = female: IABP = lntraaortic balloon pomp: M = male: PTCA = percutaneous transluminal coronary angioplasty 
class III or IV. Two patients were in cardiogenic shock: both 
had had cardiopulmonary arrest and required intubation and 
intraaortic balloon counterpulsation. 
Catheterization and angioplasty procedure. Right and left 
heart catheterization was performed by the femoral ap- 
proach. Right heart hemodynamic data were obtained with a 
Swan-Ganz catheter, and cardiac output was determined by 
the thermodilution technique. Left ventriculography was 
performed in the 30” right anterior oblique projection to 
assess left ventricular function and to semiquantitate the 
degree of mitral regurgitation. Mitral regurgitation was 
graded 0 to 4+ according to the criteria of Fuchs et al. (16). 
Angiography of both coronary vessels was performed in 
multiple views with and without angulation. Percent luminal 
narrowing was determined manually from at least two views 
with use of a caliper method before and after angioplasty. 
Coronary angioplusty was performed with the technique 
described by Gruentzig et al. (1 I), utilizing a fixed or steerable 
guide wire system. Before insertion of the guide catheter, all 
patients received 10,000 U of intravenous heparin. Three 
patients were given 25,000 to 50,000 U of intracoronary 
streptokinase during the angioplasty procedure. Right heart 
hemodynamic measurements were repeated 10 to 20 min 
after angioplasty, and the patients were transferred to the 
coronary care unit. Intravenous heparin at a mean dose of 
1,000 U/h was continued as a continuous infusion for at least 
24 h, after which vascular sheaths were removed. 
Results 
Angioplasty results. Angiographic and hemodynamic var- 
iables are detailed in Table 2. Total or subtotal occlusion 
involved a dominant left circumflex artery in three patients 
and a dominant right coronary artery in two. Angioplasty 
was performed I .5 to 8 h (mean 3.8) after the onset of chest 
pain and was successful in all patients, resulting in a reduc- 
tion in percent luminal narrowing from a mean of 99% to 30% 
(Fig. 2). Hemodynamic measurements made before and 10 to 
20 min after successful angioplasty demonstrated a marked 
Figure 1. Patient I. Chest radiographs before (A) and 2 days after 
(B) angioplasty. Note resolution of cardiomegaly and absence of 
bilateral hilar infiltrates and pulmonary venous hypertension after 
angioplasty (B). 
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Table 2. Hemodynamic and Angiographic Findings Before and After Coronary Angioplasty in Five Patients 
Patient 
No. 
Coronary 
Arteries 
Narrowed 
(no.) 
Involved 
Artery 
Degree of 
Angiographic 
MR 
Pre postt 
% Stenosis PA (mm Hg) 
Pre Post Pre Post$ 
Mean PCW 
(mm Hg) 
Pre Post$ 
V Waves 
(mm Hg) 
Pre Post$ 
EF (%) 
Pre postt 
1 I LCX 3t 0 100 20 60145 30116 32 16 50 22 48 58 
2 2 RCA 4t It 95 20 90/45 30122 50 18 70 26 60 62 
3 2 LCX 4t 0 100 30 55135 24112 30 15 45 20 40 - 
4 1 LCX 2t 0 100 20 56128 20114 26 I2 38 18 58 62 
5* 1 RCA - - 99 40 45126 28114 28 14 36 20 - - 
*Renal failure; ffollow-up angiography was performed 4 to 6 months after angioplasty; themodynamic measurements were made 10 to 20 min after 
angioplasty. CA = number of coronary arteries with 250% luminal narrowing: EF = global left ventricular ejection fraction; LCx = left circumflex artery; 
MR = mitral regurgitation: PA = pulmonary artery systolic/diastolic pressure; PCW = pulmonary capillary wedge pressure; Pre = before angioplasty; Post = 
after angioplasty; RCA = right coronary artery. 
reduction in systolic pulmonary artery pressure (from 61 ? 
17 to 26 k 4 mm Hg) and mean pulmonary capillary wedge 
pressure (from 33 k 10 to 21 k 3 mm Hg) (Fig. 3). It was 
possible to discontinue intraaortic balloon pulsation in the 
two patients soon after the procedure, and all patients were 
discharged within 12 days of angioplasty (mean hospital stay 
10.0 + 2.2 days). Left ventricular angiography was repeated 
in three patients 4 to 6 months after discharge. 
Follow-up (Table 3). Follow-up study ranged from 28 to 43 
months (mean 35 ? 6). Three patients underwent repeat right 
and left heart catheterization at 4 to 6 months (mean 5) after 
angioplasty. Angiographically, two patients (Patients 1 and 4) 
had no mitral regurgitation and one patient (Patient 2) had 
mild regurgitation (Fig. 4). No mitral regurgitation was noted 
Figure 2. Patient 3. A, Coronary angiogram in the right anterior 
oblique position showing total occlusion of the left circumflex artery 
after the first marginal branch (arrow). B, After angioplasty, a large 
posterior descending artery is visualized (arrowhead). 
on auscultation in the other two patients. Restenosis occurred 
at the site of angioplasty in two patients. Patient 4 underwent 
successful repeat angioplasty, and Patient 1 underwent coro- 
nary artery bypass grafting for restenosis without mitral valve 
replacement. Patient 2 developed severe mitral regurgitation 8 
months after angioplasty without restenosis of the dilated 
vessel and required elective mitral valve replacement. Two- 
dimensional echocardiography with Doppler ultrasound was 
performed at a mean of 24 months after angioplasty in the 
other four patients, with only a trace of mitral regurgitation 
noted in Patient 4. All patients are alive at a mean of 35 
months after angioplasty and are in functional class I. 
Discussion 
Mechanism of papillary muscle dysfunction. Mitral regur- 
gitation secondary to papillary muscle dysfunction is rela- 
tively common in patients with ischemic heart disease. 
Various degrees of mitral regurgitation have been observed 
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t’re-PTCA Post-FTCA 
Figure 3. Patient 2. Pulmonary capillary wedge tracing before and 
after angioplasty (PTCA). Prominent V waves are present before 
reperfusion. After angioplasty. mean pressure is reduced and V 
waves are no longer prominent. 
in 15% to 25% of patients with chronic myocardial &hernia 
and >50% of patients with acute myocardial infarction (3S). 
The posterior papillary muscle is more prone to ischemic 
damage because it has a single blood supply from the 
posterior descending artery, which arises from a dominant 
right coronary or left circumflex artery. The anterior papil- 
lary muscle receives a rich blood supply from branches of 
the left circumflex and left anterior descending coronary 
arteries and, therefore, rarely develops ischemic necrosis 
(2,395). 
The clinical spectrum of ischemic papillary muscle dys- 
function varies from mild dysfunction producing a transient 
midsystolic click and murmur to severe valvular regurgita- 
tion resulting in pulmonary edema and cardiogenic shock 
(5,17). Brief episodes of ischemia in the experimental model 
(18) result in mild regurgitation due to mitral valve prolapse 
secondary to relative displacement of papillary muscles 
toward the mitral valve orifice. Persistent severe ischemia 
would produce necrosis of papillary muscle and the adjacent 
myocardium, leading to incomplete leaflet coaptation and 
severe regurgitation (19). Significant ischemic papillary mus- 
cle dysfunction usually is manifested in the first few hours of 
an evolving myocardial infarction (5). Possible sequelae 
include progressive regurgitation secondary to scarring of 
the muscle or papillary muscle rupture (4,20). Rupture 
usually occurs a few days after myocardial infarction and is 
frequently associated with cardiogenic shock and a high 
mortality rate (4). 
Role of surgery in ischemic mitral regurgitation. Initial 
therapy of acute severe mitral regurgitation is directed 
toward stabilizing the patient’s condition by decreasing 
myocardial oxygen requirements and reducing left ventricu- 
lar afterload pharmacologically or mechanically with in- 
traaortic balloon pulsation. Restoration of blood supply to 
the ischemic myocardium is obligatory to prevent irrevers- 
ible necrosis of the papillary muscle. This can be achieved 
with thrombolytic agents, emergent coronary balloon angio- 
plasty or surgical revascularization. 
Numerous studies (6-10) have examined the role of mitral 
valve replacement with or without concomitant coronary 
artery bypass surgery in the treatment of severe mitral 
regurgitation secondary to ischemic papillary muscle dys- 
function or rupture. The results have been generally disap- 
pointing, with mortality rates ranging from 25% to 50% 
(6-10). In a large series of patients with acute and chronic 
ischemic mitral regurgitation, Pinson et al. (6) demonstrated 
that the severity of valvular dysfunction and the presence of 
cardiogenic shock and left heart failure were the most 
powerful predictors of early and late death after surgery. 
Early deaths were observed in >70% of patients in cardio- 
genie shock. Percent survival was significantly reduced in 
patients with ischemic regurgitation compared with that in 
patients undergoing bypass surgery and valve replacement 
for nonischemic mitral incompetence. Other studies (7-10) 
utilizing smaller numbers of patients have shown similar 
results. The operative mortality rate in patients with papil- 
lary muscle rupture appears to be even higher. 
Role of coronary angioplasty. Numerous studies (12-15) 
have demonstrated the efficacy of coronary angioplasty in 
the treatment of acute ischemic syndromes. Heuser et al. 
(21) described the successful short-term results of emergent 
angioplasty in three patients with acute ischemic mitral 
regurgitation. Angioplasty offers several advantages over 
Table 3. Clinical, Angiographic and Echocardiographic Follow-Up Data in Five Patients 
Patient 
No. 
1 
2 
3 
4 
5 
Angiographic* 
MR 
0 
It 
0 
PA* 
(mm Hg) 
26112 
36l24 
- 
25112 
- 
pew* 
(mm Hg) 
12 
18 
- 
IO 
v waves* 
(mm Hg) 
16 
24 
14 
Doppler 
Evidencet 
of MR 
0 
- 
0 
Trace 
0 
Follow-Up 
(months) 
43 
38 
34 
30 
28 
Comments 
Restenosis, CABG 
3t MR at 8 months, elective 
MVR at 12 months 
Asymptomatic 
Repeat IWA 
Asvmptomatic 
*Angiography was performed and hemodynamic measurements were obtained at a mean of 5 months after angioplasty; tDoppler study was performed at 24 
months after angioplasty. CABG = coronary artery bypass surgery; MVR = mitral valve replacement; other abbreviations as in Tables 1 and 2. 
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Figure 4. Patient 1. End-diastolic and end-systolic ventriculo- 
grams, respectively, in the right anterior oblique projection at 
presentation (A and B) and after angioplasty (C and D). The 
end-systolic frame (B) shows 3 t regurgitation into the left atrium 
(arrows); after angioplasty, no mitral regurgitation is evident (D). 
coronary bypass surgery in patients with severe ischemic 
mitral regurgitation. Reperfusion can be successfully estab- 
lished with angioplasty in this subset of patients who have a 
high operative mortality risk. Because papillary muscles 
appear to make an important contribution to regional ven- 
tricular mechanics, preservation of papillary muscles by 
angioplasty may result in improved ventricular function 
compared with conventional mitral valve replacement 
(22,23). Finally, the long-term complications of bleeding 
secondary to anticoagulation and prosthetic valve dysfunc- 
tion would also be avoided. 
No studies have compared the eficacy of pharmacologic 
versus mechanical reperfusion in the treatment of ischemic 
mitral regurgitation. The advantage of thrombolytic therapy 
is that it may result in earlier reperfusion, particularly if 
initiated by paramedics before hospitalization. The initiation 
of intravenous thrombolytic therapy in Patient 2, who had a 
long period of ischemia before angioplasty, might have 
prevented irreversible necrosis of the posterior papillary 
muscle and chronic mitral regurgitation necessitating elec- 
tive mitral valve replacement 12 months after angioplasty. 
Angioplasty would be required in patients in whom throm- 
bolytic therapy is unsuccessful or when significant mitral 
regurgitation persists secondary to a severe residual stenotic 
lesion. 
Present study. This study demonstrates the efficacy of 
emergent angioplasty in the treatment of severe mitral regur- 
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gitation secondary to ischemic posterior papillary muscle 
dysfunction. All patients had left ventricular failure, and two 
had cardiogenic shock requiring intraaortic balloon counter- 
pulsation. Angioplasty resulted in immediate improvement 
in hemodynamic variables, and all patients were discharged 
after a mean hospital stay of 10 days. Low dose intracoro- 
nary streptokinase was utilized as adjunct therapy in three 
patients to lyse angiographically visible thrombus after an- 
gioplasty. All patients were alive after a mean follow-up 
period of 35 months. and Doppler studies in four revealed a 
competent mitral valve. In Patient 2, progressive mitral 
regurgitation without restenosis developed, necessitating 
elective mitral valve replacement 12 months after angio- 
plasty. The operative findings of severe fibrosis of the 
posterior papillary muscle and the prolonged interval from 
onset of symptoms to angioplasty suggest that irreversible 
necrosis had already occurred in the muscle before reperfu- 
sion. 
Conclusions. This study is the first to demonstrate the 
efficacy and long-term benefit of emergent coronary angio- 
plasty in the treatment of ischemic mitral regurgitation. The 
high operative mortality rate in these patients suggests that 
revascularization with angioplasty or thrombolytic therapy. 
or both, may be the treatment of choice in this subset of 
patients. Further studies in a larger number of patients 
appear warranted to confirm these initial results. 
We thank Carolyn Coffey for expert secretarial assistance. 
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